Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect

Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect

Abstract We investigated the effect of angiotensin receptor neprilysin inhibitor (ARNI) on glycemic control in Korean patients. This retrospective cohort study was conducted at a single tertiary hospital. We compared the HbA1c level reduction between the ARNI and angiotensin-converting enzyme inhibi...

Full description

Bibliographic Details
Main Authors:	Heungjo Kim, Gyunam Park, Jongsung Hahn, Jaewon Oh, Min Jung Chang
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-06-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-022-13366-z

Similar Items

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
by: A.S. Ryazanov, et al.
Published: (2023-04-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine
by: Bernhard Ohnewein, et al.
Published: (2023-04-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
by: Kangbo Li, et al.
Published: (2023-02-01)

Effect of Multi-Dose Dispensing on Medication Regimen Complexity: A Real-World Study
by: Sunmin Lee, et al.
Published: (2024-02-01)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
by: Ming-Lung Tsai, et al.
Published: (2023-05-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
by: In-Jeong Cho, et al.
Published: (2021-12-01)

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
by: Alvaro Alonso, et al.
Published: (2024-03-01)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
by: Wanjing Li, et al.
Published: (2022-04-01)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
by: Singh JSS, et al.
Published: (2015-06-01)

Paramount Importance of Angiotensin Receptor Neprilysin Inhibitor in Heart Failure Management
by: Hilman Zulkifli Amin, et al.
Published: (2017-01-01)

Angiotensin receptor neprilysin inhibitor in heart failure with reduced ejection fraction: Real-world experience from a safety perspective
by: Manas Layek, et al.
Published: (2020-01-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
by: Berkay Ekici, et al.
Published: (2021-07-01)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
by: Yusuke Kashiwagi, et al.
Published: (2023-06-01)

Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation
by: Tianyu Zhu, et al.
Published: (2022-12-01)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
by: Yiwen Wang, et al.
Published: (2019-07-01)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
by: Su Yeong Park, et al.
Published: (2023-09-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
by: Nathalie Esser, et al.
Published: (2022-06-01)

Management of pulmonary hypertension associated with valvular heart disease with angiotensin‐receptor neprilysin inhibitor
by: Hyeon‐Ju Ryoo Ali, et al.
Published: (2023-10-01)

Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation
by: Youzheng Dong, et al.
Published: (2023-02-01)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime
by: Alessandra Arcudi, et al.
Published: (2022-10-01)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
by: Yuxi Sun, et al.
Published: (2022-02-01)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
by: Hyuk Kyoon Park, et al.
Published: (2023-12-01)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
by: Kun Ding, et al.
Published: (2022-05-01)

Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects
by: Donghyun Kim, et al.
Published: (2022-11-01)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
by: Alessandro Bellis, et al.
Published: (2020-11-01)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
by: Liangying Gan, et al.
Published: (2022-07-01)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
by: Sepideh Taghavi, et al.
Published: (2020-12-01)

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
by: Donna S.‐H. Lin, et al.
Published: (2021-03-01)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
by: Xiaobo Wang, et al.
Published: (2023-07-01)

Sodium–Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting
by: Gyunam Park, et al.
Published: (2022-09-01)

Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure
by: Ya-Wen Lin PhD, RN, et al.
Published: (2024-02-01)

The addition of Dapagliflozin, sodium–glucose cotransporter-2 inhibitor to angiotensin receptor blocker-neprilysin inhibitors non-responders in patient with refractory heart failure with reducedejection fraction
by: Pankaj Jariwala, et al.
Published: (2020-11-01)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
by: Amrita Mukhopadhyay, et al.
Published: (2022-12-01)

Benefits of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure with Reduced Ejection Fraction: A Longitudinal Study
by: Dharmendra Jain, et al.
Published: (2022-04-01)